Remove Clinical Development Remove Development Remove Licensing Remove Pharma Companies
article thumbnail

Laurus Labs and IIT Kanpur partner for new gene therapy products

Pharmaceutical Technology

Indian pharmaceutical company Laurus Labs has signed a memorandum of agreement (MoA) with the Indian Institute of Technology, Kanpur (IIT Kanpur) to bring new gene therapy products to the market. The company will also establish a GMP facility at IIT Kanpur’s Techno Park facility.

article thumbnail

physIQ licenses virtual trial tech to Janssen in multi-year deal

pharmaphorum

Biosensor firm physIQ has licensed its technology to Johnson & Johnson’s Janssen pharma unit in a multi-year deal, to investigate use of wearable sensors in virtual clinical trials. physIQ has a portfolio of FDA-cleared digital biomarkers and a medical-grade platform that can transform raw sensor data into clinical insight.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How patient-on-a-chip tech could be the future of drug discovery

pharmaphorum

In testing new treatments, what is promising in animal models may not transfer particularly well to humans, which helps to explain why there is a 90% failure rate during clinical development. Quris has taken its technology and used it to develop its own drug candidate pipeline. Nascent technology.

Drugs 143
article thumbnail

Novartis adds gene therapy for blindness with Gyroscope buy

pharmaphorum

Gyroscope Therapeutics and its gene therapy for the sight-robbing disease geographic atrophy (GA) has been acquired by a big pharma company – but likely not the one you would expect. Last year, it also signed a licensing deal with Dyno Therapeutics for its AAV capsid-based gene delivery technology focused on ocular diseases.

article thumbnail

Novartis taps immuno-oncology partner BeiGene for TIGIT drug

pharmaphorum

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene. Pharma companies are looking at whether blocking TIGIT as well as PD-1/PD-L1 can improve the efficacy of cancer immunotherapy.

Drugs 98
article thumbnail

Private equity firms play ‘pass the Parexel’ with $8.5bn handover deal

pharmaphorum

The CRO “successfully adapted the business to work in the midst of a global pandemic, and supported the development of therapies to combat the COVID-19 pandemic itself,” said Pamplona’s managing partner John Halsted.

article thumbnail

Enough Of Wasting Away From Cancer: Companies Gear Up To Tackle Cachexia

Delveinsight

The company has also signed a licensing agreement with Ono Pharmaceutical , a Japanese pharma company, transferring exclusive rights to develop and commercialise anamorelin in Japan, South Korea, and Taiwan. Cancer Cachexia Pipeline. Apart from the products as mentioned earlier, Tetra Bio?Pharma,